Aurobindo gets USFDA nod for arthritis drug

The product has an estimated market size of $976 million for twelve months ending November 2015

Aurobindo Pharma has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Celecoxib capsules. These capsules are used in the treatment of pain and inflammation of osteoarthritis, rheumatoid arthritis among others. 

The approved product has an estimated market size of $ 976 million for twelve months ending November 2015, according to a company press release. 

The product is a bioequivalent and therapeutically equivalent to the reference listed drug product Celebrex of GD Searle, LLC.